2025 Q4 -tulosraportti
Vain PDF
41 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 802 | - | - | ||
| 13 020 | - | - | ||
| 10 000 | - | - | ||
| 500 | - | - | ||
| 1 177 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenA bit new to the game regarding TR and therefore seeking answers from those who actually understand what I'm asking here: (using example sums below) I owned shares before the rights issue in January and bought TR for 10.000 (these are, by the way, only available on euronext and I'm struggling a bit with how to transfer them to Nordnet). In the portfolio overview on euronext, there are two holdings that are exactly alike, one under CIRCIO T.RETT, and the same under CIRCIO (but then as a separate row under the other shares in CIRCIO). The one under CIRCIO T.RETT has half the market value, let's say 5000, and the other under CIRCIO has a market value of 95.000. Here are the questions: 1. How come the two holdings are "the same", but with completely different market values? 2. What happens if I don't exercise my TR with those that now have a market value of 95.000? 3. What is best to do in this situation with TR, sell them or exercise them? I would say I've gained some understanding of what I'm holding and how I trade, but right here I'm relying on input from people who know a bit and not just my own search on the big internet😅
·3 t sittenWhen CRNA did not fall today, where one thought that conditions for warrants were set and would pull the price down, I quickly believe the bottom is set. Large volume and everyone who had a need and desire to switch from Shares to warrants had the opportunity today.
·4 t sitten · MuokattuAfter a brief review of previous presentations from August 2025, via November 2025, February 2026, as well as May 2026 ASGCT, I assess the information in these such that on Thursday we will be presented with data and a disease construct from Danon heart disease. The basis for my subjective assessment is: 1 28. August 2025 presentation. Then the "search" for relevant disease models began, and these were supposed to start towards the end of the year. Danon disease is mentioned. 2 24. November 2025 presentation H2/25 - Technical PoC Danon disease circVec construct Q1´26 – Danon disease construct first data H1/26 - circVec Danon constructs in vivo PoC data and selection Q1/26 - Select optimized Danon and AMD AAV circVec constructs 3. 24. February 2026 presentation Q2/26 - circVec-AAV in vivo PoC disease constructs for heart and eye Danon is not specifically mentioned. Reference is made to 3 other major heart diseases, but then as market opportunities. These are the ones to be licensed out/sold to Big Pharma. 4. 15. May 20026 presentation ASGCT Heart - in house - Q2´26 – circVec-AAV therapeutic construct PoC In summary: Timewise, one is now within the timeframe for the disclosure of a disease construct, and this has been reiterated most recently in the ASGCT presentation this May. Danon has been chosen - not to make money - but to document that circVec delivers as shown in all studies. Why: Danon is a Validated Target - this means that it has already been scientifically proven which gene is involved in the disease development and one can go straight to it. That is what is to be treated. One knows the target. Furthermore, this is a small disease so FDA will approve a very small study as low as 5-10 patients. The study is fast and costs little. If the phase 1 results are very good, one might possibly get approval after it or just by enrolling a few more patients. There is low technological risk, writes Circio in the November presentation. Opportunity 1: Danon disease No approvals, validated target, low technology risk Low risk is good for the study and good for the shareholders. Danon will therefore be able to serve as the final proof that circVec also delivers in humans. This is what money is being raised for now with warrants and the guarantee of 150 mill ensures that this will be carried out as planned. This is a big step for Circio and the shareholders, and on Thursday we can get the answer. You can subscribe for shares at 8,25 with warrants - after Thursday, I don't think one will be able to buy shares at a price close to that. Time will tell.
·2 t sittenGood post GR and input from others, I appreciate it. I've been thinking a lot about them announcing Thomas with "New Data". I hope it's not a matter of interpretation and that they mean the semi-new data from ASGCT from mid-May. That it really is new !
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
41 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenA bit new to the game regarding TR and therefore seeking answers from those who actually understand what I'm asking here: (using example sums below) I owned shares before the rights issue in January and bought TR for 10.000 (these are, by the way, only available on euronext and I'm struggling a bit with how to transfer them to Nordnet). In the portfolio overview on euronext, there are two holdings that are exactly alike, one under CIRCIO T.RETT, and the same under CIRCIO (but then as a separate row under the other shares in CIRCIO). The one under CIRCIO T.RETT has half the market value, let's say 5000, and the other under CIRCIO has a market value of 95.000. Here are the questions: 1. How come the two holdings are "the same", but with completely different market values? 2. What happens if I don't exercise my TR with those that now have a market value of 95.000? 3. What is best to do in this situation with TR, sell them or exercise them? I would say I've gained some understanding of what I'm holding and how I trade, but right here I'm relying on input from people who know a bit and not just my own search on the big internet😅
- ·3 t sittenWhen CRNA did not fall today, where one thought that conditions for warrants were set and would pull the price down, I quickly believe the bottom is set. Large volume and everyone who had a need and desire to switch from Shares to warrants had the opportunity today.
- ·4 t sitten · MuokattuAfter a brief review of previous presentations from August 2025, via November 2025, February 2026, as well as May 2026 ASGCT, I assess the information in these such that on Thursday we will be presented with data and a disease construct from Danon heart disease. The basis for my subjective assessment is: 1 28. August 2025 presentation. Then the "search" for relevant disease models began, and these were supposed to start towards the end of the year. Danon disease is mentioned. 2 24. November 2025 presentation H2/25 - Technical PoC Danon disease circVec construct Q1´26 – Danon disease construct first data H1/26 - circVec Danon constructs in vivo PoC data and selection Q1/26 - Select optimized Danon and AMD AAV circVec constructs 3. 24. February 2026 presentation Q2/26 - circVec-AAV in vivo PoC disease constructs for heart and eye Danon is not specifically mentioned. Reference is made to 3 other major heart diseases, but then as market opportunities. These are the ones to be licensed out/sold to Big Pharma. 4. 15. May 20026 presentation ASGCT Heart - in house - Q2´26 – circVec-AAV therapeutic construct PoC In summary: Timewise, one is now within the timeframe for the disclosure of a disease construct, and this has been reiterated most recently in the ASGCT presentation this May. Danon has been chosen - not to make money - but to document that circVec delivers as shown in all studies. Why: Danon is a Validated Target - this means that it has already been scientifically proven which gene is involved in the disease development and one can go straight to it. That is what is to be treated. One knows the target. Furthermore, this is a small disease so FDA will approve a very small study as low as 5-10 patients. The study is fast and costs little. If the phase 1 results are very good, one might possibly get approval after it or just by enrolling a few more patients. There is low technological risk, writes Circio in the November presentation. Opportunity 1: Danon disease No approvals, validated target, low technology risk Low risk is good for the study and good for the shareholders. Danon will therefore be able to serve as the final proof that circVec also delivers in humans. This is what money is being raised for now with warrants and the guarantee of 150 mill ensures that this will be carried out as planned. This is a big step for Circio and the shareholders, and on Thursday we can get the answer. You can subscribe for shares at 8,25 with warrants - after Thursday, I don't think one will be able to buy shares at a price close to that. Time will tell.·2 t sittenGood post GR and input from others, I appreciate it. I've been thinking a lot about them announcing Thomas with "New Data". I hope it's not a matter of interpretation and that they mean the semi-new data from ASGCT from mid-May. That it really is new !
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 802 | - | - | ||
| 13 020 | - | - | ||
| 10 000 | - | - | ||
| 500 | - | - | ||
| 1 177 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
41 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenA bit new to the game regarding TR and therefore seeking answers from those who actually understand what I'm asking here: (using example sums below) I owned shares before the rights issue in January and bought TR for 10.000 (these are, by the way, only available on euronext and I'm struggling a bit with how to transfer them to Nordnet). In the portfolio overview on euronext, there are two holdings that are exactly alike, one under CIRCIO T.RETT, and the same under CIRCIO (but then as a separate row under the other shares in CIRCIO). The one under CIRCIO T.RETT has half the market value, let's say 5000, and the other under CIRCIO has a market value of 95.000. Here are the questions: 1. How come the two holdings are "the same", but with completely different market values? 2. What happens if I don't exercise my TR with those that now have a market value of 95.000? 3. What is best to do in this situation with TR, sell them or exercise them? I would say I've gained some understanding of what I'm holding and how I trade, but right here I'm relying on input from people who know a bit and not just my own search on the big internet😅
- ·3 t sittenWhen CRNA did not fall today, where one thought that conditions for warrants were set and would pull the price down, I quickly believe the bottom is set. Large volume and everyone who had a need and desire to switch from Shares to warrants had the opportunity today.
- ·4 t sitten · MuokattuAfter a brief review of previous presentations from August 2025, via November 2025, February 2026, as well as May 2026 ASGCT, I assess the information in these such that on Thursday we will be presented with data and a disease construct from Danon heart disease. The basis for my subjective assessment is: 1 28. August 2025 presentation. Then the "search" for relevant disease models began, and these were supposed to start towards the end of the year. Danon disease is mentioned. 2 24. November 2025 presentation H2/25 - Technical PoC Danon disease circVec construct Q1´26 – Danon disease construct first data H1/26 - circVec Danon constructs in vivo PoC data and selection Q1/26 - Select optimized Danon and AMD AAV circVec constructs 3. 24. February 2026 presentation Q2/26 - circVec-AAV in vivo PoC disease constructs for heart and eye Danon is not specifically mentioned. Reference is made to 3 other major heart diseases, but then as market opportunities. These are the ones to be licensed out/sold to Big Pharma. 4. 15. May 20026 presentation ASGCT Heart - in house - Q2´26 – circVec-AAV therapeutic construct PoC In summary: Timewise, one is now within the timeframe for the disclosure of a disease construct, and this has been reiterated most recently in the ASGCT presentation this May. Danon has been chosen - not to make money - but to document that circVec delivers as shown in all studies. Why: Danon is a Validated Target - this means that it has already been scientifically proven which gene is involved in the disease development and one can go straight to it. That is what is to be treated. One knows the target. Furthermore, this is a small disease so FDA will approve a very small study as low as 5-10 patients. The study is fast and costs little. If the phase 1 results are very good, one might possibly get approval after it or just by enrolling a few more patients. There is low technological risk, writes Circio in the November presentation. Opportunity 1: Danon disease No approvals, validated target, low technology risk Low risk is good for the study and good for the shareholders. Danon will therefore be able to serve as the final proof that circVec also delivers in humans. This is what money is being raised for now with warrants and the guarantee of 150 mill ensures that this will be carried out as planned. This is a big step for Circio and the shareholders, and on Thursday we can get the answer. You can subscribe for shares at 8,25 with warrants - after Thursday, I don't think one will be able to buy shares at a price close to that. Time will tell.·2 t sittenGood post GR and input from others, I appreciate it. I've been thinking a lot about them announcing Thomas with "New Data". I hope it's not a matter of interpretation and that they mean the semi-new data from ASGCT from mid-May. That it really is new !
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 802 | - | - | ||
| 13 020 | - | - | ||
| 10 000 | - | - | ||
| 500 | - | - | ||
| 1 177 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt